Replies to post #408083 on Amarin Corp Plc (AMRN)

[JRoon71]

I don't think the ER (the numbers) was "disastrous". It was pretty much what we should expect. Virtually everything in it was the results of the previous management team. And without the inventory write-down and the proxy battle costs, we even made a little money.

I think the disappointment was that there was a complete lack of anything "new" to report or discuss. Literally, nothing. Same old, same old GIA strategy. Promises of revenue in Europe, promises of approval in China, more generic competition, no AG, no FDC, no MND-2119, etc. All just more of the same.

I guess I was just hoping for something to grab on to.

[FlyFishingStocks]

This is exactly what we should be seeing. Stabilizing business in the US, cutting excess costs and filing apps in very country with a human in it.

You're kidding right?

This is not what we should be seeing.
AMRN should have revenues from the EU. It's been 2 years since approval. Two years have vanished off the patent protection clock without any revenue and a colossal failure in the biggest prize - Germany
Meanwhile in the US, nothing has been done to protect turf. They talk about a few things but nothing ever materializes, hence, scripts continue to give ground to generics and revenue always misses. Of course earnings do too.
That my friend is NOT what a shareholder "should" be seeing if he is in hope of price appreciation.

i could go on,,, but that's the gist of what "you're missing"